NEW YORK â Louisville plastic surgeon M. Bradley Calobrace, MD, last week performed one of the first breast augmentations on a U.S. patients using the sixth-generation Motiva Implant, said implant maker Establishment Labs Holdings Inc.
âWith the FDA approval last week, we are experiencing high demand for Motiva Implants â both from surgeons and patients,â said Juan JosĂ© ChacĂłn-QuirĂłs, founder and CEO of Establishment Labs. âThe FDA approval came as we were attending the annual conference of the American Society of Plastic Surgeons. The response was overwhelming, and our team has already talked to more than 400 plastic surgeons post announcement.
“Since approval, we have already doubled our team to 25 sales reps across the United States, and our story of real innovation, backed by science and data, is resonating strongly. Everything we are seeing suggests that we can be the implant of choice in the United States.â
Calobrace and Caroline A. Glicksman, MD, New Jersey-based board-certified plastic surgeon, performed the first surgeries following the U.S. Food and Drug Administration approval last week of MotivaŸ SmoothSilkŸ Ergonomix and Motiva SmoothSilk Round breast implants in primary and revision breast augmentation.
âI have many patients that have been waiting a long time for Motiva approval, in some cases, for years,â Dr. Calobrace said. âI was delighted to perform one of the first Motiva breast augmentations in the United States. The innovation in these devices not only enhances aesthetics outcomes, but also significantly lowers the rates of the complications we see with other devices. Motiva implants are a game changer.â
Calobrace is a board-certified plastic surgeon, and a member of the American Society of Plastic Surgeons, the Aesthetic Society, International Society of Aesthetic Plastic Surgery, and the Kentucky Society of Plastic Surgeons. He has dual clinical faculty appointments with the Departments of Plastic Surgery, at the University of Louisville and the University of Kentucky and received teaching honors in 2007, 2011, 2014, 2015, 2016 and 2019.
Motiva Implants feature the SmoothSilk surface, which is designed for enhanced biocompatibility and scientifically shown to promote low inflammation. These 6th generation implants are offered in two distinct implant styles. Motiva SmoothSilk Ergonomix is the first breast implant in the world that embodies the science of ergonomics, as it is designed to react, feel, and move like natural breast tissue. Uniquely, their shape can adapt as the body changes position, maintaining a round shape when lying down and a teardrop shape when standing up. Motiva SmoothSilk Round implants provide increased upper breast fullness and softness while keeping a round full form regardless of position.
âThe plastic surgery community has waited more than a decade to offer breast augmentation patients in the United States something truly new,â said Dr. Glicksman, medical director of the Motiva U.S. IDE Study and a clinical trial investigator. âNow, we can confidently offer our patients implants that have consistently shown low complication rates and high patient satisfaction.â
More information about Motiva breast implants can be found at motivausa.com.
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving womenâs health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics, and breast reconstruction. The nearly four million MotivaÂź devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available.
More Kentucky business news here.
